“Very helpful reception staff, efficient processing through the appointment, and very professional treatment.”
Neovascular Glaucoma After a Retinal Vein Occlusion: Understanding the Risk Window
How Your Eye Changes After a Vein Occlusion
The steps between a blocked retinal vein and elevated eye pressure follow a recognizable pattern. Knowing that pattern helps you understand why each step of your monitoring schedule exists.
After a vein occlusion, the portions of the retina that depended on that vein stop receiving adequate oxygen. The retina responds by releasing VEGF, which travels forward through the eye and reaches structures at the front, including the iris and the drainage meshwork. The new vessels that form are thin-walled, leaky, and surrounded by a layer of fibrous tissue that can contract and close the drainage angle entirely.
Early in the process, tiny new vessel tufts appear at the edge of the pupil. They then extend into the drainage angle. As the fibrous tissue around them contracts, the angle is pulled shut and fluid can no longer leave the eye at a normal rate. Because the eye continuously produces fluid, pressure rises steadily. If pressure rises high enough and fast enough, it damages the optic nerve, which is the structure most responsible for preserving usable vision.
Not every retinal vein occlusion carries the same risk. Eyes classified as ischemic, meaning a large area of the retina has lost its blood supply, face a significantly higher likelihood of developing new vessel growth than non-ischemic eyes, where circulation loss is smaller. A dye-based imaging study called fluorescein angiography helps classify which pattern is present. Importantly, a non-ischemic result at the first visit is not permanent. Research from the Central Vein Occlusion Study found that a substantial number of eyes that looked well-perfused at the start had converted to the ischemic pattern within months to years. Monitoring continues for that reason.
If your blockage involved a branch vein rather than the central vein, your risk of neovascular glaucoma is meaningfully lower. Eyes with a branch vein occlusion are far more likely to develop retinal vessel growth or bleeding into the vitreous gel than to develop neovascular glaucoma. Hemi-central occlusions, which affect roughly half the retina, behave more like central occlusions and carry an elevated risk of iris and angle vessel growth over time. Ask your Retina Specialist which pattern applies to your eye.
Who Is Most Likely to Develop This Complication
Risk is not spread equally among everyone who has a retinal vein occlusion. Several factors, some visible at your first visit and some related to your overall health, shape how closely you need to be watched.
Certain findings at the first examination are strong predictors of who will develop neovascular glaucoma. A relative afferent pupillary defect, a finding where one pupil reacts sluggishly when light is moved between the eyes, reflects the degree of oxygen starvation in the retina and marks eyes at higher risk. Worse vision at the initial visit is also associated with greater risk. These findings guide how tight the monitoring schedule needs to be from the start.
Roughly one in four people with a central retinal vein occlusion develop new vessels on the iris. In eyes with the ischemic pattern specifically, reported rates within six months are considerably higher, with close to half developing iris vessel growth. These figures describe populations, not individuals. They explain why the schedule exists, not what will happen in your eye specifically.
Some risk factors are beyond your control, such as how much retina lost circulation at the time of the blockage. Others are not. Blood pressure, blood sugar, and cholesterol control are all part of standard care after a vein occlusion, coordinated with your primary care provider. Research has linked poorly controlled blood pressure specifically to higher rates of neovascular glaucoma after a central vein occlusion. Keeping your medical appointments, taking prescribed medications, and attending every scheduled eye exam are the most practical steps available to you.
Symptoms: What You May Feel and What You May Not
One of the most important things to understand about this complication is that it begins silently. By the time symptoms appear, pressure may already be elevated. Knowing which symptoms require same-day attention can protect your sight.
New vessels on the iris and in the drainage angle grow before eye pressure rises. In that earliest stage, there is nothing to feel and nothing unusual to see in the mirror. Only an examination with a slit-lamp microscope and a special mirrored contact lens called a gonioscope can detect them. This is also when treatment is most effective and when vessel regression is most achievable. The monitoring visit exists specifically to find this silent stage.
When pressure increases, symptoms follow. The most common complaints in neovascular glaucoma are eye pain and decreased vision, alongside redness and discomfort. A sharp pressure spike can also produce severe aching in the eye or brow, halos or rainbows around lights, headache, and nausea or vomiting. Many people are surprised that an eye problem can cause nausea, but a sudden, large rise in pressure genuinely produces that reaction.
Contact your eye doctor the same day, without waiting for a scheduled visit, if any of the following appear in the affected eye.
- Eye pain or brow ache, even if mild
- Redness that does not clear within a few hours
- Halos or rainbows around lights
- A sudden further drop in vision
- Headache combined with nausea or vomiting
- New sensitivity to light
These are warning signs of rapidly rising eye pressure. If you cannot reach your eye doctor promptly, go to an emergency room. Early treatment at this stage can preserve more vision than waiting.
How We Monitor for This Complication
Monitoring for neovascular glaucoma requires specific examinations at specific intervals. Each element of the schedule has a defined purpose, and understanding what happens at each visit makes it easier to stay committed to the plan.
The most important part of the monitoring visit takes place before dilating eye drops are used. Your Retina Specialist examines the iris under a slit-lamp microscope to look for tiny vessel tufts at the pupil margin. Gonioscopy, in which a mirrored contact lens is gently placed on the eye, allows a direct view into the drainage angle. This step is essential in ischemic eyes, in eyes with elevated pressure, and whenever iris vessel risk is high. Dilating the eye before this check can temporarily alter what is visible in the angle.
Every monitoring visit includes a measurement of eye pressure, since pressure can climb without any sensation. If pressure is elevated, the optic nerve is examined carefully and a visual field test may be ordered to check whether nerve damage has occurred. Protecting the optic nerve is the central goal of pressure management throughout this process.
Fluorescein angiography, a study in which a dye is injected into the arm and photographed as it moves through the retinal vessels, maps which areas of the retina have lost circulation. This information drives the classification of your occlusion and shapes the monitoring intensity. Optical coherence tomography (OCT), a non-invasive scan that produces detailed cross-sectional images of the retinal layers, is used at follow-up visits to track changes in the retina over time. Asking to see your own imaging can help the schedule feel more meaningful rather than routine.
After a central vein occlusion, the standard approach includes undilated iris examination and gonioscopy, along with pressure measurement and vision testing, at monthly intervals for the first six months. After anti-VEGF injections are paused or stopped, monthly monitoring resumes in ischemic eyes because the growth signal can return once treatment is discontinued. Any new eye pain or redness between visits warrants a same-day check rather than waiting for the next scheduled appointment.
Treatment: Targeting the Vessels and the Pressure
Treatment for neovascular glaucoma works on two levels at the same time: reducing the growth signal that is producing new vessels, and controlling the pressure that is rising because of them. The right combination depends on which stage of the condition is present.
Anti-VEGF injections are medications delivered directly into the vitreous gel of the eye that block the chemical signal driving new vessel growth. Agents in this class include Avastin, Lucentis, Eylea, and Vabysmo. These injections are commonly used to reduce the severity of iris and angle vessel growth and to lower the risk of further progression. Their effect on new vessels is real but temporary, which is why injections are typically paired with laser treatment rather than used alone. Research has shown that anti-VEGF therapy can delay the onset of neovascular glaucoma rather than eliminate the risk entirely.
Panretinal photocoagulation (PRP) is a laser treatment applied to the peripheral retina that reduces the oxygen-starved tissue producing the VEGF signal. When iris or retinal new vessels appear after a central vein occlusion, dense peripheral PRP is advised. It lowers the risk of vessel growth progressing and can cause existing vessels to regress. Anti-VEGF injections may be added if vessel growth continues after a complete laser treatment. PRP does not usually improve the vision you already have. Its purpose is to protect the eye from further damage.
A natural question is why laser is not applied to every high-risk eye immediately. This was studied in a clinical trial of eyes with ischemic central vein occlusion. Early preventive laser did not reliably stop new vessels from appearing. When vessels did appear in eyes that had not received preventive laser, prompt treatment at that point caused regression within one month in the majority of cases. That evidence led to the current approach: frequent monitoring with close examination, and prompt laser at the first sign of vessel growth. The monitoring schedule is itself an evidence-based decision.
Pressure control runs alongside vessel treatment. Pressure-lowering eye drops are used, but they are often insufficient on their own when vessels are actively growing or the angle has been damaged. When drops are not enough, additional options include glaucoma drainage devices (small implants that create a new drainage route), trabeculectomy (a surgical procedure that opens a new drainage pathway), and laser cyclophotocoagulation, a treatment that reduces the amount of fluid the eye produces. Which option is appropriate depends on the pressure level, the state of the drainage angle, and the amount of useful vision still present in the eye.
When new vessels are found while eye pressure is still normal and the angle is still open, treatment focuses on anti-VEGF injections and panretinal laser to stop the vessels from progressing. When pressure has already risen but the angle is still partially open, pressure-lowering medications are added alongside the vessel-directed treatments. When scar tissue has pulled the angle completely shut, drainage surgery or cyclophotocoagulation becomes necessary, and the goal may shift toward maintaining a comfortable eye at a safe pressure rather than recovering vision. In eyes with very limited remaining vision, reducing pain and discomfort is a legitimate and important goal in its own right.
Outlook and Protecting Both Eyes
Understanding what treatment can and cannot achieve helps set realistic expectations. It also opens the conversation about protecting the eye that was not affected by the occlusion.
Neovascular glaucoma is consistently described as challenging to treat, though preserving some vision is possible, particularly when the condition is detected and addressed early. Panretinal laser reliably controls new vessel growth in many cases but does not typically improve visual acuity. Vision after a central vein occlusion depends heavily on the occlusion itself and on how much retinal damage occurred before treatment began. Treatment aims to protect whatever vision remains and to keep the eye comfortable. Ask your Retina Specialist directly what is realistic for your specific situation rather than interpreting population statistics as a personal forecast.
The systemic conditions that contributed to one vein occlusion are present in both eyes. Risk of a retinal vein occlusion is higher in people over age 50 and in those with high blood pressure, diabetes, glaucoma, and hardened arteries. People who have had a vein occlusion also carry an elevated risk of cardiovascular disease overall, which is why coordination with a primary care provider is a standard part of retinal care after an occlusion. Report any sudden change in vision in the unaffected eye promptly, and do not delay seeking care.
Frequently Asked Questions
These answers address questions that often come up between visits, particularly around timing, monitoring decisions, and what to do when something feels different.
No. The 90-day label reflects the period of highest activity, not a single deadline. Cases have been documented as early as two weeks and as late as several years after the occlusion. Most occur within the first six months, but a normal examination at three months is reassuring without being final. Monitoring continues past that point precisely because the risk does not vanish. Think of 90 days as the middle of a window, not a date to count down to.
Skipping or delaying a visit during the high-risk window carries a real downside, because the earliest stage of new vessel growth produces no symptoms at all. The first vessels on the iris and in the drainage angle appear before pressure rises. That silent stage is also when treatment works best and when vessels are most likely to regress with prompt care. If a specific date does not work, call to reschedule rather than letting the visit lapse. Even a week or two of flexibility is far better than missing the appointment entirely.
Injections reduce the severity of new vessel growth at the front of the eye and lower the risk of further progression, so they provide meaningful benefit. However, research has shown that anti-VEGF therapy delays the onset of neovascular glaucoma rather than eliminating the risk. Once injections are paused or stopped, the growth signal can return, which is why monthly monitoring resumes in ischemic eyes after a treatment break. Injections and monitoring work together rather than one replacing the other.
Managing the systemic conditions linked to vein occlusion is the most direct action available. Keeping blood pressure, blood sugar, and cholesterol well controlled reduces the overall burden on retinal circulation and has been associated with lower rates of this complication. Taking those medications consistently and attending primary care appointments matters as much as the eye schedule. Beyond that, knowing the warning symptoms of rising pressure and calling your Retina Specialist the same day if they appear is the single most important thing you can do between visits.
Yes, regression is achievable and is exactly what prompt treatment aims for. In clinical research, iris and angle vessels regressed within one month of timely panretinal laser in the majority of eyes that received it at the first sign of vessel appearance. The likelihood of regression is greatest when vessels are caught early, before fibrous scar tissue has had time to pull the drainage angle shut. Once the angle is closed by scarring, treating the vessels no longer restores drainage, and pressure control requires its own surgical approach. This is the practical reason the monitoring schedule is worth keeping.
Several questions will help you understand your personal risk level and what your monitoring plan covers.
- Was my occlusion central, hemi-central, or branch?
- Does my imaging show an ischemic or non-ischemic pattern?
- Do I have a relative afferent pupillary defect?
- How often will gonioscopy and undilated iris examination be performed, and for how long?
- What is the monitoring plan after my injections are paused or stopped?
- What symptoms should prompt a same-day call rather than waiting for my next appointment?
- If my pressure rises, will I be seen by a Retina Specialist, a glaucoma specialist, or both?
Bringing a written list to your appointment helps make sure these conversations happen even when visit time is limited.
Schedule a Visit With Our Team
At Atlantic Retina Center, our fellowship-trained, board-certified Retina Specialists have deep experience managing the full spectrum of retinal vein occlusion complications, including the close monitoring and timely treatment that neovascular glaucoma requires. We see patients across five clinic locations serving the Eastern Shore of Maryland and central and southern Delaware, with the singular focus of caring exclusively for the retina, vitreous, and macula. If you have been diagnosed with a retinal vein occlusion, or if you are experiencing any of the warning symptoms described on this page, we encourage you to reach out to our team so we can help protect your vision and keep your eye comfortable.